A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease

Trial Profile

A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ESPRIT
  • Sponsors Omthera Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2013 Results published in the Clinical Therapeutics.
    • 09 Jul 2013 Positive results from this trial are included in the NDA submission to the FDA for Epanova forf the treatment of patients with very high triglyceride levels, according to an Omthera Pharmaceuticals media release.
    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top